Avita Medical, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ryan Zimmerman from BTIG maintained a Sell rating on the stock and has a $3.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ryan Zimmerman has given his Sell rating due to a combination of factors impacting Avita Medical’s financial outlook. The company’s recent quarterly results showed revenue falling short of expectations, primarily due to reimbursement challenges that have led to a decrease in demand and utilization of their RECELL product. This has prompted the company to lower its revenue guidance for the fiscal year, reflecting a cautious outlook on recovery.
Additionally, Avita Medical’s financial position is strained, with concerns about its cash reserves despite renegotiated debt terms and operational cost reductions. The transition in leadership, with Cary Vance stepping in as interim CEO, adds another layer of uncertainty. While there are some positive signs, such as progress with reimbursement rates, the overall sentiment remains cautious, leading to the Sell rating and a price target of $3.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RCEL in relation to earlier this year.